Douglas Sites has joined Rosetta Genomics as its executive vice president of sales and marketing, a newly created position. Before Rosetta, Sites was vice president of sales and marketing at Asuragen. Prior to that, he served as director of sales for hematology and oncology at Plus Diagnostics.
Nanosphere has appointed private equity investor Kristopher Wood to its board of directors.
Wood is the sole member of Highline Partners, a consultancy through which he serves as chief investment officer at Lurie Holdings, and special advisor on strategic matters to New Page Corporation.
Before forming Highline, Wood was head of strategy and corporate development at WorldColor Press, as well as an associate at the private equity firm MidOcean Partners. He also was chief acquisitions officer for Glenayre, and managing director for mergers and acquisitions and venture capital at Vertis Holdings.